Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...

DO-2 is a Best in Class MET kinase inhibitor that completed enrolling a Phase 1 dose escalation study. Tumour shrinkage is observed in 100% of MET exon 14 skip NSCLC patients without additional ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurodegenerative diseases, today announced the initiation of a first-in-human (FIH) ...